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Abstract
Mitochondria of adult cardiomyocytes appear hypo-dynamic, lack-
ing interconnected reticular networks and the continual fission
and fusion observed in many other cell types. Nevertheless,
proteins essential to mitochondrial network remodeling are abun-
dant in adult hearts. Recent findings from cardiac-specific ablation
of mitochondrial fission and fusion protein genes have revealed
unexpected roles for mitochondrial dynamics factors in mitophagic
mitochondrial quality control. This overview examines the clinical
and experimental evidence for and against a meaningful role
for the mitochondrial dynamism–quality control interactome in
normal and diseased hearts. Newly discovered functions of
mitochondrial dynamics factors in maintaining optimal cardiac
mitochondrial fitness suggest that deep interrogation of clinical
cardiomyopathy is likely to reveal genetic variants that cause or
modify cardiac disease through their effects on mitochondrial
fission, fusion, and mitophagy.
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Introduction
The proposition that mitochondria are essential to many different
aspects of normal heart functioning seems unassailable (Fig 1). Mito-
chondria are the source of ATP that fuels excitation–contraction
coupling. They sense smooth endoplasmic reticulum (ER) calcium
release to adjust metabolism and anticipate actual physical need
(Chen et al, 2012b; Dorn & Maack, 2013; Eisner et al, 2013). They
are a major source of reactive oxygen species that (depending upon
biological context and chemical concentration) can act as either phys-
iological signals or damaging cytotoxins (Eisner et al, 2013; Song
et al, 2014). Mitochondria are also the ‘gatekeepers’ of two forms of
programmed cell death, apoptosis mediated by Bcl2 family mitochon-
drial death proteins and programmed necrosis mediated by opening
of the mitochondrial permeability transition pore (Wei et al, 2001;
Whelan et al, 2012; Dorn & Kitsis, 2015). Finally, mitochondria regu-
late cardiomyocyte differentiation and embryonic cardiac develop-
ment (Kasahara et al, 2013; Cho et al, 2014). Given the multifaceted
impact of mitochondria on cardiac development, minute by minute
heart functioning, and cardiomyocyte suicide, one might predict that
genetic mutations adversely impacting mitochondrial function would
be a common cause of cardiac disease, as are mutations of sarcomeric
proteins (Seidman & Seidman, 2011). This is not the case. Indeed,
even severe primary mitochondrial diseases caused by loss-of-function
nuclear or mitochondrial DNA mutations affecting mitochondrial
electron transport chain complexes exhibit variable cardiac involve-
ment (Holmgren et al, 2003). Furthermore, the heart is generally
spared in human genetic diseases primarily impacting either the
mitophagy mitochondrial quality control pathway (e.g., Parkinson’s
disease) or the mitochondrial dynamics apparatus (e.g., Charcot–Marie–
Tooth syndrome and dominant optic atrophy) (Trinh & Farrer, 2013;
Bombelli et al, 2014). Progressive neurological degeneration, and
not heart disease, is the most common heritable feature in genetic
disorders affecting mitophagy signaling and mitochondrial dynamism.
Given that hearts are the most mitochondria-rich organ, and
indeed will only contract for a handful of cycles after interruption of
mitochondrial ATP production, it seems paradoxical that cardiac
disease is not more commonly manifested in primary mitochondrial
disorders. There are several possible explanations: First, gene–gene
and gene–environment interactions may tend to spare the heart.
Diseases of primary mitochondrial dysfunction, such as Barth syndrome
or Parkinson’s disease were originally described as Mendelian or
monogenic diseases. This appears to be an over-simplification, as
phenotypic variation within a given kindred suggests that polygenic
interactions and epigenetic factors can have a meaningful impact as
disease modifiers. Likewise, the effect of environmental factors on
mitochondrial disease can be substantial, as shown by Parkinson’s
disease that develops in some individuals exposed to pesticides
(Goldman, 2014). Second, biological redundancy within affected mito-
chondrial pathways may protect the heart, allowing for compensatory
induction of secondary metabolic, dynamism, or quality control
pathways in the context of a single genetic ‘hit’. A third, generally
overlooked, possibility is that hearts actually exhibit normal (or even
enhanced) sensitivity to mitochondrial dysfunction. Because overt heart
disease is rare in mitochondrial disorders, and neurological disease is
more common, it is widely concluded that the neurological system is
unusually sensitive, and the heart is relatively resistant, to primary
mitochondrial dysfunction. A contrary interpretation is that for
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reasons of high cardiomyocyte mitochondrial density and unavoid-
able reliance of the heart upon constant mitochondria-supplied
energy to sustain life, hearts are actually more sensitive and the
reason that cardiac involvement is not commonly observed in disor-
ders caused by severe underlying mitochondrial dysfunction is non-
viability of affected individuals and evolutionary suppression in
affected populations. In this context, the well-known metabolic plas-
ticity and robustness of normal myocardium might be better able
(than neurological tissue for example) to compensate for mitochon-
drial dysfunction in disorders caused by modest mitochondrial
dysfunction, and thus severe cardiac involvement is not observed in
the slowly progressive mitochondrial disorders that tend to attack
the neurological system. In support of this notion, Parkinson’s
disease that affects neurological, but not cardiac, function impacts
mitochondria only indirectly (i.e., by impairing their targeted elimi-
nation), and secondary mitochondrial quality control pathways have
been identified that appear to spare cardiomyocytes from the type of
cellular degeneration typically restricted to dopaminergic neurons.
In the following review, I revisit standard notions of mitochon-
drial dynamism and quality control in light of recent data elucidat-
ing important roles for mitochondrial fission and fusion in
maintaining cardiac mitochondrial fitness. Based on emerging data,
I make the case that fresh efforts employing next-generation DNA
sequencing to discover and define genetic mitochondrial defects in
unexplained cardiomyopathy (Man et al, 2013) are likely to uncover
novel rare and pathophysiologically significant primary mitochon-
drial disorders of the heart.
Overview of mitochondrial dynamism and mitophagy
Mitochondria are capable of modulating their shape and inter-
organelle connectivity by fusion or fission events. The molecular
mechanisms by which such events occur have been thoroughly
described (Chan, 2012) and are not reproduced in detail here. It is
notable, however, that cardiomyocyte mitochondria of fully devel-
oped normal hearts are ovoid in shape and not connected into the
networks observed in other cell types. Cardiomyocyte mitochondria
do not normally vary greatly in size, either as individual organelles
within the greater cell population or over time. Fission and fusion of
these organelles are sufficiently uncommon in hearts as to be nearly
impossible to observe (Dorn & Kitsis, 2015; Song & Dorn, 2015).
Thus, the heart is an exception to the often stated generalization
that mitochondria are ‘highly dynamic’ (Otera & Mihara, 2011).
Nevertheless, there is compelling inferential evidence that cardio-
myocyte mitochondria of adult mice exhibit some degree of struc-
tural dynamism: Preventing their fusion causes mitochondria to
become smaller (from unopposed fission), and preventing their
fission produces mitochondrial enlargement (from unopposed
fusion) (Song et al, 2015). Importantly, cardiomyocyte-specific
genetic interruption of either mitochondrial fusion or fission is
incompatible with mammalian life (Chen et al, 2011; Papanicolaou
et al, 2012; Kasahara et al, 2013; Kageyama et al, 2014; Ishihara
et al, 2015; Song et al, 2015). The requirement for cardiac mito-
chondrial fission and fusion factors in the absence of readily
observable cardiomyocyte mitochondrial dynamism suggests
involvement of mitochondrial fission and fusion proteins in other
essential mitochondrial functions. To provide background informa-
tion prior to examining possible alternate functioning of mitochon-
drial fission and fusion factors in hearts, I first briefly review cardiac
involvement in prototypical mitochondrial diseases.
Cardiac involvement in primary genetic mitochondrial
respiratory dysfunction
Cardiac involvement in primary mitochondrial disease is surpris-
ingly uncommon and limited to a few hallmark conditions. The
Glossary
Charcot–Marie–Tooth syndrome type 2A (CMT2A)
Degenerative neurological condition caused by loss-of-function
mutations of Mfn2 gene.
Dominant Optic Atrophy
Degenerative retinal disease caused by loss-of-function mutations of
Opa1 gene.
Dynamin-related protein 1 (Drp1)
GTPase that mediates mitochondrial fission by translocation,
oligomerization, and constriction.
Inner mitochondrial membrane (IMM)
The location of the electron transport complexes that mediated
mitochondrial respiration; Opa1 maintains IMM structure.
Mitochondrial dynamism
Fission and fusion of mitochondria, typically viewed as a cyclic
phenomenon that regulates mitochondrial shape and connectivity.
Mitofusins (Mfn)
Two closely related mitochondrial proteins that mediate the initial
steps in mitochondrial fusion: organelle tethering and outer
membrane fusion.
Mitophagy
A contraction of mitochondria and autophagy that describes multiple
mechanistically distinct processes in which cells identify and degrade
dysfunctional mitochondria to maintain overall mitochondrial fitness.
Optic atrophy 1 (Opa1)
Mitochondrial protein that mediates inner mitochondrial membrane
fusion and is important for respiratory complex integrity. Mutations
cause dominant optic atrophy.
Outer mitochondrial membrane (OMM)
The membrane interface between mitochondria and parent cell;
Parkin ubiquitinates OMM proteins, including Mfn1, Mfn2, and Drp1.
Parkin
The prototypical Parkinson’s disease factor that, via its E3 ubiquitin
ligase activity, plays a central role in PINK1/Parkin-mediated
mitophagy.
Parkinson’s disease
Chronic degenerative neuromuscular condition; early heritable forms
are caused by loss-of-function mutations in genes encoding
mitophagy factors Parkin or PINK1.
PTEN-induced putative kinase 1 (PINK1)
Mitochondrial kinase that is preferentially stabilized in dysfunctional
organelles to initiate mitophagy signaling via the Parkin pathway
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prototypical genetic mitochondrial disease affecting the heart is
Barth syndrome, caused by mutations in the TAZ gene (Barth
et al, 1983). The encoded protein, tafazzin, is a mitochondrial
inner membrane phospholipid transacylase involved in cardio-
lipin maturation (Vreken et al, 2000). This X-linked disease is
extremely rare (~1/300,000 births) and is characterized by
neutropenia, cardiac and skeletal myopathies, growth delay, and
elevated urine levels of 3-methylglutaconic acid (Cantlay et al,
1999). Cardiac involvement in the form of dilated or hyper-
trophic cardiomyopathy, with or without arrhythmias, is seen in
over 90% of subjects (Roberts et al, 2012). Ventricular non-
compaction/hyper-trabeculation has been described (Towbin,
2010). Mitochondria in Barth syndrome patients show hyper-
proliferation and partial dissipation of the inner membrane
potential (Xu et al, 2005). In a Drosophila Barth syndrome
model, indirect flight muscle mitochondria exhibited abnormal
cristae (Xu et al, 2006) similar to the stacks of electron-dense
cristae described in soleus muscles of a TAZ shRNA mouse
model (Soustek et al, 2011); cardiac mitochondria are greatly
enlarged. Mitochondrial proliferation, aggregation, and abnormal
cristae are also observed in a TAZ shRNA mouse (Acehan et al,
2011). The specific mitochondrial mechanisms that cause cardiac
and skeletal myopathies in Barth syndrome have not yet been
described.
A second example of heart disease provoked by primary genetic
mitochondrial dysfunction is Friedreich’s ataxia. This autosomal
recessive neurodegenerative disease is caused by triplet nucleotide
repeat expansions within the FXN gene, encoding the mitochondrial
matrix iron chaperone protein frataxin (Campuzano et al, 1996;
Durr et al, 1996). Loss of frataxin leads to dysfunction of iron clus-
ter proteins in mitochondrial electron transport chain complexes I,
II, and III (Rotig et al, 1997) (Fig 2). In addition to progressive
dorsal sensory nerve degeneration and ataxia, hypertrophic cardio-
myopathy is seen in a majority of patients; heart failure is the termi-
nal diagnosis in approximately one-third of affected individuals
(Kipps et al, 2009; Tsou et al, 2011). Cardiac mitochondria in
Friedreich’s ataxia undergo massive proliferation with decreased
ATP production (Lodi et al, 2001; Bunse et al, 2003), consistent
with functional compromise of the electron transport chain. Primary
mitochondrial defects and cardiomyopathy of Friedreich’s ataxia
are faithfully recapitulated in mouse models (Puccio et al, 2001;
Whitnall et al, 2008).
Cardiac abnormalities are increasingly being discovered in
disorders caused by mutations in mitochondrial DNA (mtDNA).
The human mitochondrial genome is a ~16,500-bp circular double-
stranded mini-chromosome on which are encoded 13 proteins of
the electron transport system (Fig 2), 2 ribosomal RNAs, and 22










Figure 1. Schematic depiction of the extensive and varied impact of mitochondria on cell processes.
Mechanistic details of how mitochondria produce ATP and ROS are shown in Fig 2.
ª 2015 The Author EMBO Molecular Medicine Vol 7 | No 7 | 2015
Gerald W Dorn II Mitochondrial dynamics in hearts EMBO Molecular Medicine
867
maternal lineage, and therefore, mutations in mtDNA are
maternally inherited. It is estimated that 1/5,000 individuals have
some form of mtDNA mutational disease, approximately 50% of
which will exhibit atypical hypertrophic cardiomyopathy with or
without conduction disease (Elliott et al, 2008; Limongelli et al,
2010).
Mitochondrial proliferation and functional impairment are
common features underlying cardiac disease in Barth syndrome,
Friedreich’s ataxia, and mtDNA mutation disease. It has been
suggested that increased mitochondrial mass contributes to cardio-
myocyte dysfunction by creating an internal resistance element
(Wredenberg et al, 2002; Russell et al, 2004; Sebastiani et al, 2007).
Progressive cardiac hypertrophy (Limongelli et al, 2010) in these
primary mitochondrial diseases might be therefore explained as
follows: Primary mitochondrial respiratory impairment can initially
be compensated for, but over time is aggravated by secondary
stochastic mitochondrial damage. The double hit of intrinsic mito-
chondrial dysfunction and age-related impairment provokes
compensatory mitochondrial biogenesis, manifested as mitochon-
drial proliferation. Abnormal accumulation of interfibrillar mito-
chondria increases internal resistance to cardiomyocyte shortening,
thereby stimulating cardiac hypertrophy. This mechanism, while
consistent with the available data, remains speculative at this time.
Genetically manipulated mouse models might be used to test the
hypothesis that mitochondrial proliferation, in the absence of respi-
ratory dysfunction, can physically impede unloaded cardiomyocyte
shortening.
Absence of cardiac phenotypes in primary disorders of
mitochondrial quality control
The archetypal human disorder linked to a primary defect in mito-
chondrial fitness is early-onset autosomal recessive Parkinson’s
disease caused by loss-of-function mutations of either the PARK2
(encoding Parkin) or PARK6 (encoding PINK1) genes (Lees et al,
2009). Parkin and PINK1 are central effectors for targeted mito-
phagic elimination of dysfunctional mitochondria (Youle &
Narendra, 2011). As illustrated in Fig 3, PINK1 kinase is selectively
stabilized in mitochondria that have diminished electrochemical
potential across their inner membrane, recruits Parkin to mitochon-
dria, and activates its E3 ubiquitin ligase activity. Parkin-mediated
ubiquitination of mitochondrial outer membrane proteins is the
signal for organelle engulfment by autophagosomes and subse-
quent transfer to degradative lysosomes, from whence the compo-
nents are either recycled or disposed. Interruption of PINK1/
Parkin-mediated mitophagy, as by loss-of-function Parkinson’s
disease mutations, suppresses a major mechanism for maintaining
the overall quality of mitochondrial health: selective elimination of
dysfunctional mitochondria. Epidemiologically, mutations of the
Parkin gene are the major cause of early-onset hereditary Parkin-
son’s disease; PINK1 gene mutations are a less common cause
(Lees et al, 2009). Mutations of either mitophagy factor induce
degeneration and loss of dopaminergic neurons of the substantia
nigra and locus coeruleus (Gesi et al, 2000). The underlying















































Figure 2. The mitochondrial electron transport chain (ETC.) and its relationship to ROS production.
Each of the inner mitochondrial membrane (IMM) ETC. enzymatic complexes is colored and indicated by their respective roman numerals (I-V). Electrons are transferred
between complexes (dotted arrows), promoting proton (H+) transport (dashed arrows) from the matrix to the intermembrane space. Proton flow through ATP synthase
(complex V) converts ADP to ATP. Normally, O2 is the terminal electron (e
) acceptor from complex IV. Electron leak from complexes I or III of damaged mitochondria can
produce toxic reactive O2 and H2O2. Friedreich’s ataxia is caused bymutations in frataxin that induces dysfunction in complexes I, II, and III. Mitochondrial DNAmutations can
affect complexes I, III, IV, and V, but not complex II that is comprised entirely of nuclear-encoded proteins.
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to cell damage from damaged mitochondria that were not properly
eliminated, and therefore for the primarily neurological aspects of
the disease, are poorly understood. Whereas mitophagy-defective
mitochondria in iPSc-derived neurons from these patients appear
overly abundant and dysmorphic (Seibler et al, 2011; Imaizumi
et al, 2012; Rakovic et al, 2013), similar abnormalities are
observed in cultured fibroblasts and skeletal muscle biopsies of
patients with Parkin gene mutations (Ahlqvist et al, 1975; van
der Merwe et al, 2014). Despite evidence for multi-system
involvement, cardiac involvement in Parkinson’s disease has only
been inferred from statistical associations (Zesiewicz et al, 2004;
Perez-Lloret et al, 2014).
The prototypical human diseases caused by interruption of mito-
chondrial fusion are Charcot–Marie–Tooth syndrome type 2A
(CMT2A) and autosomal dominant optic atrophy (DOA). These heri-
table disorders have been linked to loss-of-function mutations in the
mitochondrial fusion proteins, Mfn2 and Opa1, respectively (Burte
et al, 2015). Mfn2 is one of two outer mitochondrial membrane
GTPases that mediate mitochondrial tethering and outer membrane
fusion, the first two events in organelle fusion (Chen & Chan, 2005).
Additionally, Mfn2 uniquely bridges mitochondria to endo/
sarcoplasmic reticulum, thus facilitating inter-organelle calcium
transport and signaling (de Brito & Scorrano, 2010; Dorn & Maack,
2013; Dorn et al, 2015). Finally, PINK1-phosphorylated Mfn2 can
act as the mitochondrial receptor for Parkin, giving it a role in
mitophagy signaling (Chen & Dorn, 2013; Song et al, 2014) (Fig 3).
Because of this multi-functionality, MFN2 mutations have the
potential to adversely impact mitochondrial structure by interrupt-
ing organelle fusion, calcium uptake by interrupting ER/SR mito-
chondrial crosstalk, or mitophagy signaling by interrupting Parkin
signaling (Fig 3).
As with Barth syndrome and Friedreich’s ataxia, mitochondrial
proliferation is frequently described in CMT2A (Renaldo et al,
2012); the mitochondria themselves may be either reduced in size
(Renaldo et al, 2012) or enlarged (Rouzier et al, 2012). Although
CMT2A is classically described as a degenerative neurological
disease of peripheral motor neurons with variable sensory nerve
involvement, there can be substantial phenotypic overlap between
CMT2A (typically caused by mutations of MFN2) and DOA (typi-
cally caused by mutations of OPA1); retinal involvement is
described in 12% of CMT2A patients with confirmed MFN2 muta-
tions (Bombelli et al, 2014). Histological studies of skeletal muscle
showing impaired mitochondrial functional integrity (using a stain
for cytochrome oxidase activity) suggest that muscle involvement
can be extensive (Rouzier et al, 2012). However, the question of
whether myocardium is similarly affected in CMT2A caused by
MFN2 mutations remains unanswered.
As introduced, DOA is a disease caused by truncation mutations
of the mitochondrial inner membrane fusion protein, Opa1 (Chen &
Chan, 2010; Yu-Wai-Man & Chinnery, 2013). In addition to promot-
ing IMM fusion, Opa1 plays a critical role for maintaining cristae
structure and thereby in maintaining functional integrity of respira-
tory complexes located on the IMM (Pellegrini & Scorrano, 2007;
Cogliati et al, 2013). Conventionally, DOA is characterized by loss
of inner retinal ganglion cells, degeneration of the optic nerve, and
progressive central loss of vision. Patients with a variant disorder
called ‘DOA plus’ exhibit multi-system involvement with myopathy
and peripheral neuropathy (Amati-Bonneau et al, 2008). This again
demonstrates phenotypic overlap between CMT2A (caused by muta-
tions of the outer mitochondrial membrane fusion protein Mfn2)
and DOA (caused by mutations of the inner mitochondrial fusion
protein Opa1). Manipulation of the homologous Drosophila genes
has been useful in uncovering differences in the cell pathology
induced by outer vs. inner mitochondrial membrane fusion defects.
Thus, suppressing reactive oxygen species (ROS) markedly
improves eye and heart tube phenotypes induced by RNAi-mediated
Opa1 suppression, but not by mitofusin suppression (Yarosh et al,














































Figure 3. Molecular crosstalk between mitochondrial fusion and Parkin-
mediated mitophagy.
A damaged/depolarized mitochondrion is shown in which PINK1 kinase levels
have stabilized, resulting in phosphorylation of Mfn2 and its recruitment of
Parkin. Poly-ubiquitination of outer mitochondrial membrane proteins by Parkin
initiates mitophagy, ultimately resulting in lysosomal degradation.
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myopathies induced by mitofusin deficiency in Drosophila are
improved by enhancing the ability to handle ER stress (Bhandari
et al, 2014b; Debattisti et al, 2014), which was ineffective in Opa1
insufficiency.
Insights from genetic mouse models
The virtual absence of clinical cardiac disease in genetic disorders
of mitochondrial quality control (Parkinson’s disease) and mito-
chondrial dynamism (Charcot–Marie–Tooth syndrome) seems
inconsistent with cardiac involvement in mitochondrial diseases
such as Barth syndrome and Friedreich’s ataxia that are linked to
respiratory chain dysfunction. In trying to understand the reasons
for these differences, it is worth noting that the seemingly straight-
forward functional subclassification of PINK1 and Parkin mutations
as principally affecting mitochondrial quality control, and Mfn2 and
Opa1 mutations as primarily impacting mitochondrial dynamism,
may be misleading. In addition to mitophagy, PINK1/Parkin signal-
ing can provoke mitochondrial fragmentation (Deng et al, 2008;
Poole et al, 2010; Yu et al, 2011; Rana et al, 2013; Buhlman et al,
2014; Sugiura et al, 2014). Likewise, PINK1-phosphorylated Mfn2
helps recruit Parkin to damaged mitochondria during mitophagy
(Chen & Dorn, 2013; Chen et al, 2014), and mitochondrial fission
induced by Drp1 appears to be essential for normal mitochondrial
quality control (Song et al, 2015). Thus, functional overlap between
pathways allows for different interpretations of genetic ablation
studies.
Before examining the phenotypes obtained after tissue-specific
ablation of mitochondrial fusion or fission factors, it may be
useful to review lessons learned from cell biology that preceded
the in vivo studies. Unlike the ovoid individual mitochondria of
cardiomyocytes, many cells have interconnected filamentous mito-
chondrial networks. These networks undergo structural remodel-
ing via fission-mediated disassembly and fusion-mediated re-
assembly. When fission and fusion are at equilibrium, overall
mitochondrial size is stable (Fig 4). Fibroblasts typically have
elongated organelles with a length/width aspect ratio of ~6 (Song
et al, 2015). Increasing mitochondrial fusion and/or inhibiting
organelle fission will result in elongated mitochondria and
increased network interconnectivity. Under these conditions, mito-
chondrial networks may even appear continuous throughout the
cell (Song et al, 2015). Conversely, inhibiting mitochondrial fusion
and/or increasing the rate of organelle fission results in numerous
unconnected shorter organelles, commonly referred to as ‘frag-
mented mitochondria’ (Chen et al, 2003; Ishihara et al, 2009;
Song et al, 2009, 2015). It is generally accepted that increased
mitochondrial connectivity produced by shifting the balance of
mitochondrial dynamism toward either more fusion or less fission
represents a more physiological condition, and that less connectiv-
ity or fragmentation provoked by increased fission or impaired
fusion is pathological. In other words, mitochondrial fusion is
‘good’, but mitochondrial fission is ‘bad’. The notion that frag-
mented mitochondria are detrimental probably derives from early
observations that mitochondria networks undergo fission-mediated












Figure 4. Mitochondrial structure and the role of mitochondrial dynamism in fibroblasts and cardiomyocytes.
A prototypical fibroblast-like cell is shown at the top with interconnected filamentous mitochondria (green). Mitochondrial hyper-connectivity occurs if the balance between
fission and fusion is shifted toward fusion (left), whereas fragmentation occurs if the balance is shifted toward fission (right). Normal adult cardiomyocytes (bottom) have
intrinsically ‘fragmented’ mitochondria and lack observable organelle remodeling.
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fission to programmed cell death (Suen et al, 2008). Consistent
with this idea, inhibition of Drp1-induced mitochondrial fission
using mdivi-1 or other agents can protect against cardiac or brain
injury after ischemic damage (Lackner & Nunnari, 2010; Ong
et al, 2010; Disatnik et al, 2013; Guo et al, 2013; Sharp et al,
2014). Furthermore, fragmented mitochondria of mitofusin-deficient
MEFs appear partially depolarized, reflecting compromised
respiratory function, whereas mitochondria of Mfn1 or Mfn2
single null MEFs appear fully polarized and only modestly shorter
than normal (Chen et al, 2003; Song et al, 2007, 2015). Thus,
there appears to be a direct relationship between mitochondrial
fusion and mitochondrial health. Indeed, as Mfn1 and Mfn2 can
interact both homo- and hetero-typically, overexpressing Mfn1
largely corrects abnormalities caused by the absence of Mfn2, and
vice versa, and the modest disturbance in mitochondrial
morphometry in single Mfn1 or Mfn2 knockout MEFs (Chen et al,
2003) is likely the consequence of an insufficiency in total mitofusin
protein (analogous to haploinsufficiency of two functionally
synonymous genes).
Accumulating evidence suggests that the proposition that
mitochondrial fusion is ‘good’ and fission is ‘bad’ is an over-
simplification and that cell death linked to mitochondrial fission is
contextual: First, adult cardiomyocyte mitochondria are intrinsically
fragmented in comparison with other cells, that is, they are typically
small (aspect ratio ~1.5) and not connected into networks (Fig 4).
Nevertheless, hearts function well and cardiomyocyte apoptosis is
not normally observed. Second, highly fused mitochondria exhibit
greater sensitivity to staurosporine-stimulated apoptosis, not protec-
tion as would be predicted based on conventional wisdom (Szabadkai
et al, 2004). Third, genetic deficiency of the mitochondrial fusion
factor Mfn2 actually protects against cell necrosis (Whelan et al,
2012). And finally, spontaneous mitochondrial fragmentation
induced by Drp1 overexpression fails to provoke meaningful patho-
logy, at least in Drosophila cardiomyocytes (Bhandari et al, 2014b).
Changes in mitochondrial shape and connectivity after genetic
mitofusin ablation in vitro (Chen et al, 2005) or in vivo (Chen et al,
2007, 2010; Pham et al, 2012) may not therefore be the only (or
actual) cause of observed cellular dysfunction and disease pheno-
types.
Examining the consequences of interrupting mitochondrial fusion
raises further considerations. Mitochondrial fusion is the opposite of
fission. Thus, if it is correct that fission is detrimental, then it is
common sense that fusion should be beneficial. For example, a
fusion event between one damaged and one undamaged mitochon-
drion has the potential to dilute out damaged components in the
former, thereby repairing the damaged organelle via the process of
‘functional complementation’ (Youle & van der Bliek, 2012).
However, this schema ignores the potential for bidirectional
exchange of components. Accordingly, a fusion event between a
damaged and healthy organelle would not only dilute out the
damaged components in the former, but contaminate the healthy
components of the latter; fusion has the potential to harm the origi-
nally healthy organelle to the same extent that it benefits the
impaired one. Indeed, our laboratory recently demonstrated fusion-
mediated contamination of good mitochondria by bad, which we
refer to as ‘mitochondrial contagion’. In these studies, heart tube
dysfunction and loss of mitochondrial fitness in Parkin-deficient
Drosophila cardiomyocytes were delayed by inhibiting mitochondrial
fusion through RNA-mediated suppression of the Drosophila mitofu-
sin, MARF (Bhandari et al, 2014a). Thus, in this instance,
mitochondrial fusion was detrimental and its inhibition was thera-
peutic. Accumulating data indicate that mitochondrial fusion and
fission are neither inherently good or bad, but that a proper balance
between the two is important both in cells with interconnected mito-
chondrial networks and in cardiomyocytes.
In vivo mitofusin deletion
Deleting mitofusin genes that encode essential OMM mitochondrial
fusion proteins was predicted to impair mitochondrial fusion.
However, because Mfn1 and Mfn2 can mutually substitute for one
another as mitochondrial tethers and OMM fusion proteins (Chen
et al, 2003), only their combined ablation abrogates Mfn-mediated
mitochondrial fusion. Nevertheless, germ line ablation of either
Mfn1 or Mfn2 genes is embryonic lethal, likely because the absence
of either mitofusin adversely impacts placental development (Chen
et al, 2003). For this reason, the expanding body of knowledge
regarding consequences of in vivo loss of mitofusins derives from
conditional gene ablation using the floxed allele mice generated by
David Chan and colleagues (Chen et al, 2007). In general, combined
Mfn1/Mfn2 ablation in neurons (Chen et al, 2007), skeletal muscle
(Chen et al, 2010), and myocardium (Chen et al, 2011), which
should provoke total loss of mitochondrial fusion in the affected cell
types (Chen & Chan, 2010), produced severe abnormalities, whereas
individual deletion of either Mfn1 or Mfn2 in the same tissues
produced comparatively minor effects in the same tissues (Chen
et al, 2007, 2010, 2012b) (Chen & Dorn, 2013). For example,
combined ablation of Mfn1 and Mfn2 in skeletal muscle induced
skeletal myopathy with mitochondrial fragmentation, increased
mtDNA mutations, loss of mtDNA, and mitochondrial proliferation
(Chen et al, 2010). From this constellation of findings, it was
concluded that loss of mitochondrial fusion causes instability in
mitochondrial DNA and provokes compensatory mitochondrial
proliferation. However, recent findings that deletion of Mfn2 (either
alone or in combination with Mfn1) can directly impair mitochon-
drial quality control suggest an additional contributory mechanism.
Notwithstanding major functional redundancies between Mfn1
and Mfn2 as promoters of mitochondrial fusion in MEFs, there are
intriguing differences when the two mitofusins are individually
deleted in mouse tissues using Cre-lox strategies. In dopaminergic
neurons, Slc6a3-Cre-mediated deletion of floxed Mfn1 was well
tolerated, whereas deletion of Mfn2 provoked mitochondrial
abnormalities, neuronal death, and a Parkinson’s disease-like neuro-
muscular phenotype (Pham et al, 2012). Likewise, ablating mitofusins
in the dopaminergic neurons of floxed allele mice using a dopamine
amino transferase (DAT)-Cre transgene (Lee et al, 2012) revealed
that Mfn1 deletion is well tolerated, whereas loss of Mfn2 evoked
severe locomotor defects and early lethality. Intriguingly, mitochondria
of Mfn2-deficient neurons were markedly enlarged, and not
fragmented as would be anticipated if Mfn2 deletion had prompted
a mitochondrial fusion defect. Importantly, Mfn2-deficient neuronal
mitochondria specifically exhibited a defect in Parkin binding (Lee
et al, 2012).
The results obtained after Mfn1 or Mfn2 ablation in the brain
resemble those of cardiac-specific Mfn1 and Mfn2 deletion. Cardio-
myocyte Mfn1 deficiency is well tolerated, but cardiomyocyte Mfn2
deficiency causes mitochondrial enlargement (Papanicolaou et al,
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2011; Chen et al, 2012b; Chen & Dorn, 2013) with increased
mitochondrial ROS production (Song et al, 2014) and an interrup-
tion of normal cytosolic–mitochondrial Parkin translocation (Chen
& Dorn, 2013). A common theme from these studies is that loss of
Mfn2 induces more severe phenotypes than loss of Mfn1, suggesting
some action of Mfn2 in addition to its titular role in promoting mito-
chondrial fusion. Indeed, since interfering with mitochondrial fusion
produces mitochondrial shortening both in vitro and in vivo (Chen
et al, 2003, 2011; Song et al, 2015), mitochondrial enlargement in
multiple models of organ-specific in vivo Mfn2 insufficiency seems
to rule out defective fusion as the principal causal mechanism.
In vivo Drp1 deletion
If the conventional notion is correct that smaller fragmented mito-
chondria are ‘bad’ and that larger more interconnected mitochon-
dria are ‘good’, then genetic interruption of mitochondrial fission by
ablating Drp1 should be beneficial (as was the case with pharmaco-
logical Drp1 inhibition in cardiac ischemic injury (Disatnik et al,
2013; Ong et al, 2010)). However, the results of four recent studies
that examined the consequences of ablating Drp1 in mouse hearts
provide additional evidence that larger mitochondria are not neces-
sarily better mitochondria. Three groups independently deleted
Drp1 in cardiomyocytes by combining Drp1 floxed allele mice with
either constitutive or tamoxifen-inducible a-myosin heavy chain Cre
transgenes (Kageyama et al, 2014; Ikeda et al, 2015; Song et al,
2015). As expected, Drp1-deficient cardiomyocyte mitochondria
were enlarged (from unopposed mitochondrial fusion). Unexpect-
edly, cardiomyopathies developed in each study and were linked in
different ways to disturbances of mitochondrial autophagy. In a
fourth study, neonatal cardiomyopathy developed in mice with a
more generalized muscle-specific deletion of Drp1 (Ishihara et al,
2015). Thus, cardiomyocyte-specific in vivo inhibition of mitochon-
drial fission has revealed another level of crosstalk between mito-
chondrial dynamism and quality control.
The most straightforward explanation for how defective mito-
chondrial fusion or fission can adversely impact mitophagy is that
an intact fission–fusion cycle is essential for asymmetric mitochon-
drial fission in which damaged or malfunctioning mitochondrial
components are segregated from healthy components and targeted
for removal (Twig et al, 2008; Dorn, 2015) (Fig 5). However, a
fission–fusion cycle defect does not explain why Mfn2 ablation
produces greater mitochondrial dysfunction than Mfn1 ablation (see
above), or reveal why Parkin translocation defects in neurons and
cardiomyocytes are exclusively evoked by Mfn2 deficiency (Lee
et al, 2012; Pham et al, 2012; Chen & Dorn, 2013). A molecular
mechanism was provided by our observation that Mfn2 is enabled
as a mitochondrial-localized binding protein for Parkin after its
phosphorylation by the PINK1 kinase (Chen & Dorn, 2013). PINK1
is preferentially stabilized in damaged/depolarized mitochondria,
with the consequence that Parkin translocates to that organelle and
stimulates its mitophagy by ubiquitinating mitochondrial proteins
(see Fig 3; Narendra et al, 2010). In our in vivo studies, Mfn2 is an
essential intermediate in the interaction between mitochondrial
PINK1 and cytosolic Parkin, being phosphorylated by the former
and thereby transformed into a mitochondrial binding partner for
the latter (Chen & Dorn, 2013). The dual role of Mfn2 as both
mitochondrial fusion factor and Parkin receptor in the mito-
phagy appears sufficient to explain mitochondrial enlargement,
degeneration, and proliferation in Mfn2 deficiency in the heart
(Dorn & Kitsis, 2015) and brain (Lee et al, 2012).
In vivo Opa1 deletion
Mitofusins and Drp1 mediate the initial steps of mitochondrial fusion
and fission, respectively. However, complete mitochondrial integra-
tion after OMM fusion requires Opa1-mediated fusion of the IMM.
Intriguingly, insufficiency of Opa1 produces cardiac phenotypes in
Drosophila and mice that are distinct from those induced by mito-
fusin ablation. Perhaps these differences are attributable to impor-






Figure 5. Asymmetric fission for mitochondrial quality control.
A damaged or senescent mitochondrion (mixture of damaged yellow/orange and
healthy green components) is shown. Via asymmetric fission, the healthy
components are delivered to one daughter that is fusion-competent,
rejuvenated, and retained. The damaged components are segregated into the
other, smaller daughter that is depolarized and promptly eliminated via
mitophagy.
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membrane fusion, such as being a critical modulator of cristae archi-
tecture (and therefore of respiratory complex functioning) (Frezza
et al, 2006; Cogliati et al, 2013). Consistent with this reasoning,
germ line Opa1 haploinsufficiency in mice induces mitochondrial
fragmentation and ROS production with an age-dependent cardio-
myopathy (Chen et al, 2012a). The importance of respiratory
compromise and ROS production in heart disease provoked by Opa1
deficiency was demonstrated in Drosophila heart tubes wherein
RNAi-mediated Opa1 suppression produced not only small mito-
chondrial dysmorphology and cardiomyopathy, but markedly
increased cardiomyocyte ROS production. Suppressing cardio-
myocyte mitochondrial ROS production with transgencially expressed
superoxide dismutase improved the cardiomyopathy, whereas
enhancing the ability of heart tubes to manage ER stress had no
effect. This is the reciprocal approach to the one that improved the
cardiomyopathy of Drosophila mitofusin deficiency in the same
study; ROS inhibition was ineffective, whereas improving the ER
stress response rescued heart tube dysfunction (Bhandari et al,
2014b). Thus, unlike deficiency of OMM mitofusin proteins that
impairs culling of dysfunctional mitochondria exhibiting age-related
or extrinsic damage, Opa1 deficiency induces primary mitochondrial
respiratory dysfunction, in part by producing poorly tolerated abnor-
malities of cristae respiratory supercomplexes.
Mouse models of primary mitophagic dysfunction
Functional crosstalk between mitochondrial dynamics and mito-
phagy pathways complicates interpretation of cardiac gene manipu-
lation studies. The following questions arise: Are resulting
phenotypes the direct consequence of altering the balance between
mitochondrial fission and fusion? Are they an indirect effect that
perturbing mitochondrial dynamism exerts on mitochondrial quality
control signaling? Answers to these questions may be found in stud-
ies of mice lacking the two central effectors of mitophagy, PINK1,
and Parkin.
Germ line deletion of the murine PINK1 gene provoked progres-
sive cardiac dysfunction beginning at 2 months of age (Billia et al,
2011). Although apoptosis was reported as being increased, the
overall cardiac phenotype was cardiac hypertrophy, and not
dilated cardiomyopathy that typically results from increased
cardiomyocyte death. Mitophagy was not measured, but dimin-
ished mitochondrial respiratory function and respiratory complex
content and increased oxidative stress are consistent with
decreased mitochondrial quality. Notably, mitochondrial size was
increased. Thus, interruption of mitophagy by PINK1 deletion is
detrimental to hearts.
Germ line ablation of the Parkin gene is perhaps most notewor-
thy for the absence of major phenotypes, cardiac, neurological, or
otherwise. None of the multiple types of Parkin knockout mice
develop a Parkinson’s disease-like phenotype (Dawson et al, 2010),
perhaps because of opportunistic compensation by related E3
ubiquitin ligases (Bhandari et al, 2014a) or other mitophagy factors
(Shin et al, 2011). Nevertheless, modest cardiac and cardiomyocyte
mitochondrial abnormalities were detected in 1-year-old Parkin null
mice (Hoshino et al, 2013; Kubli et al, 2013). Taken together, these
early findings in germ line PINK1 and Parkin knockout mice suggest
that a common constellation of cardiac defects develops when
mitophagy is impaired in cardiac myocytes. At the organelle level,
there is accumulation of structurally abnormal, enlarged, dysfunc-
tional mitochondria; at the organ level, there is a relatively modest
and slowly progressive cardiomyopathy. These findings are similar
to those provoked by cardiac Mfn2 deficiency that interrupts
PINK1/Parkin signaling by deleting the mitochondrial Parkin recep-
tor (Chen & Dorn, 2013; Song et al, 2014) and are striking in their
contrast to the rapidly progressive and lethal cardiomyopathy
induced by complete interruption of mitochondrial fusion (combined
Mfn1 and Mfn2 gene ablation) (Chen et al, 2011; Papanicolaou
et al, 2012). It seems reasonable to postulate that interruption of the
mitochondrial fission–fusion cycle by combined ablation of both
Mfn1 and Mfn2 (fusion-deficient), or deletion of Drp1 (fission-
deficient), evokes severe and acutely deleterious effects on the heart
that include, but are not limited to, interrupted mitochondrial qual-
ity control (Chen et al, 2011; Song et al, 2015). By comparison,
deletion of Mfn2, PINK1, or Parkin evokes a chronic form of cardiac
degeneration through loss of an important mechanism to maintain
mitochondrial fitness, mitophagic culling. Cardiac degeneration
produced by interrupting the PINK1/Mfn2/Parkin mitophagy
pathway may be chronic and delayed because Parkin-independent
pathways for mitochondrial quality control, such as the incom-
pletely understood ROS-dependent mitophagy pathway (Song et al,
2014), are invoked but ultimately overwhelmed.
Implications of experimental findings for clinical medicine
Barth syndrome, Friedreich’s ataxia, and cardiac involvement in
mtDNA disease are examples of primary mitochondrial dysfunction
that adversely impact the heart. In each of these conditions, mito-
chondrial respiratory chain dysfunction is a central pathological
feature. In other disorders such as Parkinson’s disease, CMT2A,
and DOA, the principal abnormality is not at the mitochondrion,
but within the mitochondrial cell signaling interface that maintains
fitness of the mitochondrial pool. Although mitochondrial respira-
tory dysfunction is measurable in cells derived from patients with
these disorders and in the respective fly and mouse genetic models,
the heart is seemingly spared from major involvement. Or perhaps
not. A review of published literature reveals almost no direct
information on cardiomyopathy in Parkinson’s disease, CMT2A, or
DOA (despite compelling evidence for skeletal muscle involvement
in all three syndromes), and cardiac phenotypes have been
described in mice lacking the causal genes for each of these
neurodegenerative conditions. Given the rapid technical advances
in deep sequencing of exomes and whole genomes, we may
discover unsuspected mitochondrial involvement in hereditary
cardiac and skeletal myopathies that are not explained by the usual
common genetic disturbances in sarcomeric proteins, dystrophin,
etc. Indeed, reports are beginning to surface of severe congenital
cardiomyopathies attributed to primary abnormalities of mitochon-
drial respiratory chain function (Dhar et al, 2013; Garcia-Diaz et al,
2013).
Biology is complex, and complex things are by definition not
simple. While this would appear to be stating the obvious, our
tendency as researchers and clinicians can be to follow Occam’s
razor and default to the simplest explanation, assuming that it will
be the best. Sometimes, however, simplicity just reflects a position
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low on the learning curve, and with additional knowledge a more
complex and elegant conceptual paradigm is engendered. We are
currently witnessing this type of evolutionary thinking about
primary mitochondrial involvement in heart disease, and of cardiac
involvement in primary mitochondrial disease. The conventional
functional distinction between mitochondrial dynamism and quality
control pathways is an example of how straightforward concepts are
giving way to a more elegant understanding of integrated biological
processes governing mitochondrial homeostasis. The concept of a
mitochondrial dynamism–mitophagy interactome (Dorn & Kitsis,
2015) may be helpful in understanding phenotypic overlap and
mechanistic uncertainties. Mfn2 is both a pro-fusion protein with
effects similar to Mfn1 and an important factor in Parkin-mediated
mitophagy. A mutation that impairs only the pro-fusion activity of
Mfn2 might have little effect because residual Mfn1 can compensate.
But if it acts as a dominant inhibitor of Mfn1- and Mfn2-mediated
fusion, an MFN2 mutation might completely interrupt outer
membrane fusion, phenocopying combined Mfn1/Mfn2 ablation.
Alternately, a mutation in Mfn2 that specifically affects Parkin bind-
ing might disrupt mitophagy while preserving mitochondrial fusion.
The point is, in no instance is the effect of the human point muta-
tion faithfully recapitulated by something as crude as MFN2 gene
ablation. For this reason, as rare mutations of mitochondrial dynam-
ics and mitophagy factors are identified in disease cohorts, defining
the causal disease mechanism will require a more complete under-
standing of the complex interplay between these (and other) path-
ways. This may best be accomplished for in vitro cell-based and
in vivo murine experimental platforms using gene editing knockin,
rather than knockout approaches.
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